Management of Metastatic Cervical Cancer: Review of the Literature
- 10 July 2007
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (20), 2966-2974
- https://doi.org/10.1200/jco.2006.09.3781
Abstract
This article reviews the English-language literature concerning chemotherapy for advanced, recurrent, or metastatic cervix carcinoma. Specifically, it reviews the available literature for active single agents, doublets, triplets, and multiple drug combination chemotherapy. Until recently, single-agent cisplatin was the drug of choice in metastatic cervix cancer. Various doublets, triplets, and quartlets have been reported to have higher objective response rates than single-agent cisplatin when compared in phase III clinical trials. Some have demonstrated improvements in progression-free survival, but only topotecan plus cisplatin has demonstrated an improvement in overall survival. This benefit is most apparent in patients who have a long disease-free interval from primary therapy and who have not received prior cisplatin as a radiosensitizer.Keywords
This publication has 81 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysisThe Lancet, 2001
- International incidence rates of invasive cervical cancer before cytological screeningInternational Journal of Cancer, 1997
- Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapyGynecologic Oncology, 1991
- Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinomaGynecologic Oncology, 1989
- Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatinCancer, 1989
- A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: A gynecologic oncology group studyGynecologic Oncology, 1989
- Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1985
- Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology groupCancer, 1981